Screener
Amneal Pharmaceuticals, Inc. AMRX Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001723128-26-000031
FAQ
- What is Amneal Pharmaceuticals, Inc.'s cash & equivalents?
- Amneal Pharmaceuticals, Inc. (AMRX) reported cash & equivalents of $127.64M in Q2 2026.
- How has Amneal Pharmaceuticals, Inc.'s cash & equivalents changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s cash & equivalents increased by 78.4% year-over-year, from $71.54M to $127.64M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Amneal Pharmaceuticals, Inc.'s cash & equivalents has grown at a -3.7% compound annual growth rate (CAGR), from $341.38M to $282.03M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Amneal Pharmaceuticals, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude